Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

T cell antigen receptor vaccines for active therapy of T cell malignancies Conference on Basic and Clinical Relevant Biology of Cutaneous T Cell Lymphoma Reddy, S. A., Okada, C., Wong, C., Bahler, D., Levy, R. NEW YORK ACAD SCIENCES. 2001: 97–105

Abstract

T cell lymphoproliferative disorders continue to be serious management problems, and so alternative therapeutic modalities are continuously being explored. One such strategy involves immunotherapy using the T cell receptor (TCR) as a target. Specifically we are attempting to develop a T cell receptor idiotype (TCR-Id) vaccine because the TCR-Id can serve as a tumor-specific antigen. In this article we will briefly review the rationale for TCR-Id vaccines, the preclinical models as developed in our laboratory, and a discussion of our current plans for a vaccine trial in mycosis fungoides.

View details for Web of Science ID 000172619000010

View details for PubMedID 11594586